Skip to main content

Advertisement

Log in

Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Rotigotine, a non-ergot dopamine receptor agonist, offers potential for continuous dopaminergic stimulation that could avoid the fluctuations observed with traditional treatments. We conducted a randomized, double-blind, placebo-controlled trial in Japanese patients with advanced Parkinson’s disease (PD) to investigate the efficacy and safety of rotigotine. Inclusion criteria included the presence of motor complications, such as wearing off, on–off, delayed-on/no-on, any circumstances that could interfere with levodopa dose escalation because of side effects, or declining levodopa efficacy. The enrolled patients received once-daily applications of rotigotine transdermal patches or matched placebo patches. A total of 174 patients were randomly assigned to rotigotine (87 patients) or placebo (87 patients). The full analysis set included 172 patients (86 for the rotigotine group and 86 for the placebo group). The maximum maintenance dose of rotigotine was set at 16 mg/24 h. The changes in unified PD rating scale Part III scores from baseline to the end of the trial were −10.1 ± 9.0 (mean ± standard deviation) in the rotigotine group and −4.4 ± 7.4 in the placebo group (p < 0.001). There was a significantly greater reduction in the off-time (p = 0.014) in the rotigotine group. Rotigotine was well tolerated, with serious adverse events being reported in only three patients in each group. Rotigotine at doses of up to 16 mg/24 h is efficacious and safe in Japanese patients with advanced PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. New Engl J Med 276:374–379

    Article  CAS  PubMed  Google Scholar 

  2. Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. New Engl J Med 339:1044–1053

    Article  CAS  PubMed  Google Scholar 

  3. Marsden CD, Parkes JD (1976) “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1:292–296

    Article  CAS  PubMed  Google Scholar 

  4. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458

    Article  CAS  PubMed  Google Scholar 

  5. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491

    Article  CAS  PubMed  Google Scholar 

  6. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284:1931–1938

    Article  Google Scholar 

  7. Parkinson Study Group (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053

    Google Scholar 

  8. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M et al (2006) Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 21:343–353

    Article  PubMed  Google Scholar 

  9. Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE et al (1992) Continuous lisuride effects on central dopaminergic mechanisms in Parkinson’s disease. Ann Neurol 32:776–781

    Article  CAS  PubMed  Google Scholar 

  10. Engber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168:291–298

    Article  CAS  PubMed  Google Scholar 

  11. Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci 23(Suppl):109–115

    Article  Google Scholar 

  12. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 5:677–687

    Article  CAS  PubMed  Google Scholar 

  13. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn-Schmiedebergs Arch Pharmacol 379:73–86

    Article  CAS  PubMed  Google Scholar 

  14. Boroojerdi B, Wolff HM, Braun M, Scheller DKA (2010) Rotigotine transdermal patch for the treatment of Parkinson’s disease and restless legs syndrome. Drugs Today 46:483–505

    Article  CAS  PubMed  Google Scholar 

  15. Pfeiffer RF (2002) Potential of transdermal drug delivery in Parkinson’s disease. Drugs Aging 19:561–570

    Article  CAS  PubMed  Google Scholar 

  16. Cawello W, Braun M, Boekens H (2009) Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 37:2055–2060

    Article  CAS  PubMed  Google Scholar 

  17. Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M et al (2008) Thorough QT/QTc study in patients with advanced Parkinson’s disease: cardiac safety of rotigotine. Clin Pharmacol Ther 84:595–603

    Article  CAS  PubMed  Google Scholar 

  18. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34:966–978

    Article  CAS  PubMed  Google Scholar 

  19. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E et al (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513–520

    Article  CAS  PubMed  Google Scholar 

  20. LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68:1262–1267

    Article  CAS  PubMed  Google Scholar 

  21. Pagano M, Gauvreau K (2000) Principles of biostatistics, 2nd edn. Duxbury Press, Belmont

    Google Scholar 

  22. Food and Drug Administration, HHS (2005) International conference on harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 70:61134–61135

Download references

Acknowledgments

This trial was supported by Otsuka Pharmaceutical Co., Ltd., Japan.

Conflicts of interest

YM is a Professor of Neuroregenerative Medicine, a position donated by Nippon Boehringer Ingelheim Co., Ltd. and Medtronic Japan Co., Ltd., at Kitasato University School of Medicine. YM is also an advisory board member for Nippon Boehringer Ingelheim Co., Ltd., FP Pharmaceutical Corporation, Otsuka Pharmaceutical Co., Ltd., Abbott Japan Co., Ltd., and Kyowa Hakko Kirin Co., Ltd., and he received personal compensation for attending advisory board meetings. MN received speaker’s honoraria from Dainippon Sumitomo Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd. TK received honoraria, support for travel to meetings, and fees for participation in review activities from FP Pharmaceutical Corporation, Novartis Pharma K.K., GlaxoSmithKline K.K., Nippon Boehringer Ingelheim Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. KH received personal compensation for attending advisory board meetings from Otsuka Pharmaceutical Co., Ltd. MM received honoraria for consulting and/or lecturing from GlaxoSmithKline K.K., Nippon Boehringer Ingelheim Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd. MT received honoraria for consulting from Otsuka Pharmaceutical Co., GlaxoSmithKline K.K., and UCB Japan Co. Ltd. NH is an advisory board member for Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Kyowa Hakko Kirin Co., Ltd., and MSD K.K., and has received honoraria from Nippon Boehringer Ingelheim Co., Ltd., GlaxoSmithKline K.K., Novartis Pharma K.K., FP Pharmaceutical Corporation, Takeda Pharmaceutical Company Limited., Janssen Pharmaceutical K.K., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Dainippon Sumitomo Pharma Co., Ltd. JI and TT are employees of Otsuka Pharmaceutical Co., Ltd.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masahiro Nomoto.

Additional information

On behalf of the Rotigotine Trial Group. Members of the Rotigotine Trial Group are listed in Appendix.

Appendix: Members of the SPM 962 Rotigotine Trial Group

Appendix: Members of the SPM 962 Rotigotine Trial Group

The authors wish to thank the following additional members of the SPM 962 Rotigotine Trial Group, who participated in this trial as investigators: Takashi Kimura, Hidenao Sasaki, Mikio Shoji, Takashi Abe, Atsushi Takeda, Itaru Toyoshima, Kazuo Yoshizawa, Toshiaki Kamitani, Kimihito Arai, Shigeki Tanaka, Sadako Kuno, Fusako Yokochi, Hiroshi Kurisaki, Noriko Kawashima, Shinji Ohara, Kouichi Mizoguchi, Toshihiko Ohashi, Tetsushi Atsumi, Akira Inukai, Tatsuya Hattori, Hideyuki Sawada, Harutoshi Fujimura, Nobuyoshi Yoshikawa, Sonoko Nozaki, Mitsutoshi Yamamoto, Hiroaki Miyaoka, Masahiro Nagai, Noriko Nishikawa, Tatsuo Yamada, Naokazu Sasagasako, Takayuki Kondo, Shigehiro Imamura, Yoshito Sonoda, Satoshi Takahashi, and Hitoshi Yamada.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nomoto, M., Mizuno, Y., Kondo, T. et al. Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J Neurol 261, 1887–1893 (2014). https://doi.org/10.1007/s00415-014-7427-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-014-7427-3

Keywords

Navigation